Morgan Stanley raised its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 44.6% during the first quarter, Holdings Channel reports. The institutional investor owned 474,185 shares of the biotechnology company’s stock after buying an additional 146,220 shares during the period. Morgan Stanley’s holdings in BioCryst Pharmaceuticals were worth $3,983,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of BCRX. Principal Financial Group Inc. increased its stake in BioCryst Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock worth $111,000 after buying an additional 45 shares during the last quarter. American International Group Inc. increased its position in BioCryst Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 45,230 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 2,989 shares in the last quarter. Trexquant Investment LP increased its position in BioCryst Pharmaceuticals by 39.3% in the first quarter. Trexquant Investment LP now owns 50,791 shares of the biotechnology company’s stock valued at $427,000 after buying an additional 14,333 shares in the last quarter. Swiss National Bank increased its position in BioCryst Pharmaceuticals by 18.7% in the first quarter. Swiss National Bank now owns 114,300 shares of the biotechnology company’s stock valued at $960,000 after buying an additional 18,000 shares in the last quarter. Finally, Teachers Advisors LLC increased its position in BioCryst Pharmaceuticals by 18.5% in the fourth quarter. Teachers Advisors LLC now owns 125,777 shares of the biotechnology company’s stock valued at $796,000 after buying an additional 19,615 shares in the last quarter. 84.72% of the stock is currently owned by institutional investors.

Shares of BioCryst Pharmaceuticals, Inc. (BCRX) traded up 0.88% on Tuesday, hitting $4.61. The stock had a trading volume of 78,607 shares. The stock has a 50 day moving average price of $5.32 and a 200-day moving average price of $6.27. The company’s market cap is $370.77 million. BioCryst Pharmaceuticals, Inc. has a 12-month low of $3.75 and a 12-month high of $9.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.02. BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. The firm had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $5.79 million. During the same period in the previous year, the firm posted ($0.22) earnings per share. The firm’s revenue for the quarter was down 35.4% on a year-over-year basis. On average, equities analysts expect that BioCryst Pharmaceuticals, Inc. will post ($0.72) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/biocryst-pharmaceuticals-inc-bcrx-shares-bought-by-morgan-stanley/1491718.html.

BCRX has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a report on Tuesday, April 18th. Needham & Company LLC reiterated a “hold” rating on shares of BioCryst Pharmaceuticals in a report on Friday, May 19th. Noble Financial reiterated a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Sunday, May 28th. BidaskClub upgraded BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, HC Wainwright restated a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 8th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. BioCryst Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $8.00.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.